Blurred menus at dim restaurants and squinting at fine print are hallmarks of aging vision, but researchers at UC Irvine believe that decline may not be inevitable. A new study demonstrates that injecting a specific fatty acid into the eyes of aging mice restored their visual function, opening a potential path toward reversing age-related sight loss in humans.
The work centers on a gene called ELOVL2, long recognized as a biological marker of aging. As people grow older, their bodies produce less of a fatty acid substance the retina needs to function properly. When these levels drop, vision deteriorates and the risk of age-related macular degeneration, a leading cause of vision loss in older adults, climbs sharply.
Previous research showed that boosting ELOVL2 activity in older mice improved their ability to see. But the new approach sidesteps that enzyme altogether. Instead of trying to activate ELOVL2, researchers tested whether they could simply supply aging eyes with the missing fatty acids directly.
The results exceeded expectations. Older mice that received injections of a specific polyunsaturated fatty acid showed measurable improvements in visual performance. Critically, the team found that supplying DHA, another common omega-3 fatty acid often promoted for eye health, did not produce the same benefit.
"What is important is that we didn't see the same effect with DHA," said Dorota Skowronska-Krawczyk, an associate professor at UC Irvine who led the work. "We have this other fatty acid that is seemingly working and improving vision in aged animals."
The discovery carries practical implications beyond treating existing vision problems. The researchers identified genetic variants in ELOVL2 linked to faster progression of age-related macular degeneration. This finding could eventually allow doctors to identify which patients face the highest risk of vision loss and intervene early with fatty acid therapy.
Skowronska-Krawczyk believes ELOVL2 belongs on the short list of genes that should be central to anti-aging research across the board. Her team is already exploring whether the same lipid supplementation approach could slow aging in the immune system, where early studies suggest ELOVL2 deficiency accelerates cellular aging and may influence blood cancers.
The work was published in Science Translational Medicine and involved collaborators from the Polish Academy of Sciences and a German medical university. While the proof-of-concept was demonstrated in mice, the pathway to human trials remains unclear, and years of additional testing typically precede such advances in medical treatment.
Author Jessica Williams: "If this holds up in humans, a simple injection could spare millions from the slow, frustrating reality of dimming vision in their later years."
Comments